Profiles

Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Deborah Hall and Christopher Goetz.

 
Connection Strength
 
 
 
1.275
 
  1. Pal G, Mangone G, Ouyang B, Ehrlich D, Saunders-Pullman R, Bressman S, Alcalay RN, Marder K, Aasly J, Mouradian MM, Anderson S, Bernard B, Stebbins G, Sani S, Afshari M, Verhagen L, de Bie RMA, Foltynie T, Hall D, Corvol JC, Goetz CG. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 Jun 10.
    View in: PubMed
    Score: 0.245
  2. Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, Ehrlich D, Saunders-Pullman R, Shanker V, Bressman S, Alcalay RN, Garcia P, Marder KS, Aasly J, Mouradian MM, Link S, Rosenbaum M, Anderson S, Bernard B, Wilson R, Stebbins G, Nichols WC, Welter ML, Sani S, Afshari M, Verhagen L, de Bie RMA, Foltynie T, Hall D, Corvol JC, Goetz CG. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.238
  3. Hill EJ, Goetz CG, Stebbins GT, Hagerman R, Ouyang B, Hall DA. Placebo Response in Fragile X-associated Tremor/Ataxia Syndrome. Mov Disord Clin Pract. 2020 Apr; 7(3):298-302.
    View in: PubMed
    Score: 0.209
  4. Hall DA, Stebbins GT, Jacquemont S, Berry-Kravis E, Goetz CG, Hagerman R, Zhang L, Leehey MA. Clinimetric Properties of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale. Mov Disord Clin Pract. 2019 Feb; 6(2):120-124.
    View in: PubMed
    Score: 0.193
  5. Hall DA, Forjaz MJ, Golbe LI, Litvan I, Payan CAM, Goetz CG, Leentjens AFG, Martinez-Martin P, Traon AP, Sampaio C, Post B, Stebbins G, Weintraub D, Schrag A. Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Mov Disord Clin Pract. 2015 Jun; 2(2):127-134.
    View in: PubMed
    Score: 0.150
  6. Voigt RM, Wang Z, Brown JM, Engen PA, Naqib A, Goetz CG, Hall DA, Metman LV, Shaikh M, Forsyth CB, Keshavarzian A. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 Aug; 170:105780.
    View in: PubMed
    Score: 0.061
  7. Manfready RA, Forsyth CB, Voigt RM, Hall DA, Goetz CG, Keshavarzian A. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.061
  8. Manfready RA, Engen PA, Verhagen Metman L, Sanzo G, Goetz CG, Hall DA, Forsyth CB, Raeisi S, Voigt RM, Keshavarzian A. Attenuated Postprandial GLP-1 Response in Parkinson's Disease. Front Neurosci. 2021; 15:660942.
    View in: PubMed
    Score: 0.057
  9. Pal GD, Hall D, Ouyang B, Phelps J, Alcalay R, Pauciulo MW, Nichols WC, Clark L, Mejia-Santana H, Blasucci L, Goetz CG, Comella C, Colcher A, Gan-Or Z, Rouleau GA, Marder K. Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. Mov Disord Clin Pract. 2016 Sep-Oct; 3(5):465-471.
    View in: PubMed
    Score: 0.039
  10. Berry-Kravis E, Goetz CG, Leehey MA, Hagerman RJ, Zhang L, Li L, Nguyen D, Hall DA, Tartaglia N, Cogswell J, Tassone F, Hagerman PJ. Neuropathic features in fragile X premutation carriers. Am J Med Genet A. 2007 Jan 01; 143A(1):19-26.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.